NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

IceCure Medical Ltd (ICCM) Stock Analysis

IceCure Medical Ltd (ICCM) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ICCM

$1.08

+$0.03 (+2.86%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ICCM with… →

ICCM Key Statistics

As of Oct 21, 2026
Trading
Open
$1.05
Previous Close
$1.05
Day's Range
1.05–1.12
52-Week Range
0.96–25.20
Volume
92.21K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.43
Valuation
Market Cap
$5.01M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.27
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.84
Financials (FY)
Revenue (FY)
$3.38M+2.67%
Net Income (FY)
−$15.06M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.64M
1-Year Return
−95.68%
Dividend and dates
Earnings Date
November 18, 2026
Avg Volume
143.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ICCM closed at $1.08, −95.68% over 1 year.

IceCure Medical Ltd (ICCM) has a market capitalization of $5.01M.

In fiscal 2025, ICCM reported revenue of $3.38M.

ICCM Stock Return by Calendar Year

IceCure Medical Ltd (ICCM) return since Aug 2021: what $10,000 became

1 year
$10,000 $432
−95.68%
5 years
$10,000 $57
−99.43%
Since Aug 2021
$10,000 $33
−99.67%

If you had invested $10,000 in IceCure Medical Ltd (ICCM) at the close on August 26, 2021, the earliest close on record here, it would have been worth $33 at the close on October 21, 2026: −99.67% in total, −67.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−94.10%
2025−44.55%
2024+2.80%
2023−30.97%
2022−49.18%
2021 (partial year)−72.02%

As of October 21, 2026.

ICCM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.38M−$15.06M−445.6%
2024$3.29M−$15.32M−465.5%
2023$3.23M−$14.65M−453.8%
2022$3.09M−$16.98M−550.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.38M$1.23M−$15.09M−$15.06M−445.6%
2024$3.29M$1.45M−$15.70M−$15.32M−465.5%
2023$3.23M$1.30M−$15.58M−$14.65M−453.8%
2022$3.09M$1.45M−$16.74M−$16.98M−550.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ICCM Valuation vs Medical Devices Median

Median of 145 stocks
MetricICCMMedical Devices medianvs median
P/S ratio1.272.5350% below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values IceCure Medical Ltd (ICCM) at $5.01M. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 67.

The most recent close on file for ICCM is $1.08, dated October 21, 2026. That is +$0.03 (+2.86%) against the previous close. The 52-week range on file runs from $0.96 to $25.20. The latest close sits 12.5% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $3.38M. That is +2.67% against the prior fiscal year, when revenue was $3.29M. The same year closed with a net loss of $15.06M. Earnings per share on a trailing basis come to −6.84.

Across the 4 fiscal years on file, revenue moves from $3.09M in 2022 to $3.38M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1.27 times revenue. On price-to-sales that is 49.83% below the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

Over the trailing twelve months the total return is −95.68%. Across 5 years the annualized return works out at −64.48%. The reported beta is 0.43. Daily returns over the trailing 5 years annualize to a volatility of 155.13%.

Growth & Income

No dividend is on file for ICCM.

The strongest complete calendar year on file is 2024 at +2.80%; the weakest is 2022 at −49.18%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −94.10%.

Peer Comparison

IceCure Medical Ltd (ICCM) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IceCure Medical Ltd ICCM $5.01M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. IceCure Medical Ltd has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About IceCure Medical Ltd

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

Visit website →